{"id":172,"date":"2023-03-08T16:00:47","date_gmt":"2023-03-08T15:00:47","guid":{"rendered":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance-copy\/"},"modified":"2023-03-13T14:45:26","modified_gmt":"2023-03-13T13:45:26","slug":"pharmacogenetique","status":"publish","type":"page","link":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/","title":{"rendered":"Pharmacog\u00e9n\u00e9tique"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1678287706456{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb]\n<p style=\"text-align: center;\">L\u2019unit\u00e9 de pharmacog\u00e9n\u00e9tique propose une activit\u00e9 de <strong>g\u00e9notypage<\/strong> afin de pouvoir <strong>d\u00e9tecter ou comprendre l\u2019absence de r\u00e9ponse \u00e0 un traitement pharmacologique<\/strong> ou, au contraire, <strong>identifier le risque de survenue d\u2019effets ind\u00e9sirables<\/strong> m\u00e9dicamenteux chez certains patients.<\/p>\n[\/vc_column_text][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-phone\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb custom_color=\u00a0\u00bb#23b093&Prime; css=\u00a0\u00bb.vc_custom_1678715104859{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb][vc_column_text]\n<p style=\"text-align: center;\"><strong>05 49 45 49 71<\/strong><\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-users\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb custom_color=\u00a0\u00bb#23b093&Prime; css=\u00a0\u00bb.vc_custom_1677678607372{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb][vc_column_text]\n<p style=\"text-align: center;\"><strong>Responsable de l&rsquo;unit\u00e9 de pharmacog\u00e9n\u00e9tique <\/strong>: Dr Claire Lafay-Chebassier<br \/>\n<strong>Equipe :<\/strong>\u00a0 collaboration avec le laboratoire de g\u00e9n\u00e9tique du CHU de Poitiers<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_tta_accordion shape=\u00a0\u00bbsquare\u00a0\u00bb active_section=\u00a0\u00bb13&Prime; no_fill=\u00a0\u00bbtrue\u00a0\u00bb collapsible_all=\u00a0\u00bbtrue\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbActivit\u00e9s principales\u00a0\u00bb tab_id=\u00a0\u00bb1677667701778-183ccba4-8256&Prime;][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-search\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb custom_color=\u00a0\u00bb#23b093&Prime; css=\u00a0\u00bb.vc_custom_1678287940040{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb][vc_column_text]\n<ul>\n<li>Recherche de polymorphismes de la TPMT ou Thiopurine S-M\u00e9thylTransf\u00e9rase, dont l\u2019indication est le d\u00e9pistage d\u2019un d\u00e9ficit avant traitement par l\u2019azathioprine ou la 6-mercaptopurine et la recherche suite \u00e0 une toxicit\u00e9 apparue sous ces m\u00eames traitements<\/li>\n<li>Recherche de polymorphismes de la DPD (Dihydropyrimidine deshydrog\u00e9nase), dont l\u2019indication est le d\u00e9pistage d\u2019un d\u00e9ficit avant traitement par 5-FU ou cap\u00e9citabine ou l\u2019explication d\u2019une toxicit\u00e9 s\u00e9v\u00e8re apparue sous ces m\u00eames traitements. Activit\u00e9 en lien avec le Laboratoire de toxicologie et pharmacocin\u00e9tique du CHU de Poitiers<\/li>\n<li>Recherche d\u2019un polymorphisme de l\u2019UGT1A1 (UDP-Glucuronosyl Transf\u00e9rase 1A1), dont l\u2019indication est le d\u00e9pistage d\u2019un d\u00e9ficit avant mise en route d\u2019un traitement par l\u2019irinot\u00e9can ou l\u2019explication d\u2019une toxicit\u00e9 s\u00e9v\u00e8re apparue sous ce m\u00eame traitement<\/li>\n<li>Autres g\u00e9notypages possibles sur demande des cliniciens<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbEnseignement\/Recherche\u00a0\u00bb tab_id=\u00a0\u00bb1677667701797-5b72ea78-95e1&Prime;][vc_column_text]Activit\u00e9 de recherche de pharmacog\u00e9n\u00e9tique de diff\u00e9rents d\u00e9sordres psychiatriques en lien avec l\u2019Unit\u00e9 INSERM U1084 \u2013 Laboratoire de Neurosciences Exp\u00e9rimentales et Cliniques :<\/p>\n<ul>\n<li>G\u00e9notypage dans le cadre des projets cliniques sur le Trouble Obsessionnel Compulsif (TOC) et le Trouble Anxieux G\u00e9n\u00e9ralis\u00e9 (TAG) de polymorphismes portant sur 5-HTT, BDNF, CYP2C19<\/li>\n<li>G\u00e9notypage dans le cadre de projet clinique sur l\u2019addiction au tabac de polymorphismes portant sur CHRNB2, CHRNA3, CHRNA4, CHRNA5, CYP2A6<\/li>\n<li>G\u00e9notypage dans le cadre de projet clinique sur l\u2019addiction au cannabis de polymorphismes portant sur CYP2C9, CYP2C19, CYP3A4, FAAH, CB1, CB2, TRPV1<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbRessources\u00a0\u00bb tab_id=\u00a0\u00bb1677667748290-2339e5f1-2377&Prime;][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][vc_btn title=\u00a0\u00bbR\u00e9seau francophone de pharmacog\u00e9n\u00e9tique RNPGx\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Frnpgx.shinyapps.io%2FRNPGx%2F||target:%20_blank|\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1678287706456{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb] L\u2019unit\u00e9 de pharmacog\u00e9n\u00e9tique propose une activit\u00e9 de g\u00e9notypage afin de pouvoir d\u00e9tecter ou comprendre l\u2019absence de r\u00e9ponse \u00e0 un traitement pharmacologique ou, au contraire, identifier le risque de survenue d\u2019effets ind\u00e9sirables m\u00e9dicamenteux chez certains patients. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-172","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmacog\u00e9n\u00e9tique - Pharmacologie clinique et vigilances<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacog\u00e9n\u00e9tique - Pharmacologie clinique et vigilances\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1678287706456{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb] L\u2019unit\u00e9 de pharmacog\u00e9n\u00e9tique propose une activit\u00e9 de g\u00e9notypage afin de pouvoir d\u00e9tecter ou comprendre l\u2019absence de r\u00e9ponse \u00e0 un traitement pharmacologique ou, au contraire, identifier le risque de survenue d\u2019effets ind\u00e9sirables m\u00e9dicamenteux chez certains patients. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmacologie clinique et vigilances\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-13T13:45:26+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/pharmacogenetique\\\/\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/pharmacogenetique\\\/\",\"name\":\"Pharmacog\u00e9n\u00e9tique - Pharmacologie clinique et vigilances\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/#website\"},\"datePublished\":\"2023-03-08T15:00:47+00:00\",\"dateModified\":\"2023-03-13T13:45:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/pharmacogenetique\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/pharmacogenetique\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/pharmacogenetique\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"CHU de Poitiers\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Services\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/services\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pharmacologie clinique et vigilances\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Pharmacog\u00e9n\u00e9tique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/#website\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/\",\"name\":\"Pharmacologie clinique et vigilances\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmacog\u00e9n\u00e9tique - Pharmacologie clinique et vigilances","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/","og_locale":"fr_FR","og_type":"article","og_title":"Pharmacog\u00e9n\u00e9tique - Pharmacologie clinique et vigilances","og_description":"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1678287706456{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb] L\u2019unit\u00e9 de pharmacog\u00e9n\u00e9tique propose une activit\u00e9 de g\u00e9notypage afin de pouvoir d\u00e9tecter ou comprendre l\u2019absence de r\u00e9ponse \u00e0 un traitement pharmacologique ou, au contraire, identifier le risque de survenue d\u2019effets ind\u00e9sirables m\u00e9dicamenteux chez certains patients. [&hellip;]","og_url":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/","og_site_name":"Pharmacologie clinique et vigilances","article_modified_time":"2023-03-13T13:45:26+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/","url":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/","name":"Pharmacog\u00e9n\u00e9tique - Pharmacologie clinique et vigilances","isPartOf":{"@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/#website"},"datePublished":"2023-03-08T15:00:47+00:00","dateModified":"2023-03-13T13:45:26+00:00","breadcrumb":{"@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/pharmacogenetique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"CHU de Poitiers","item":"https:\/\/www.chu-poitiers.fr\/"},{"@type":"ListItem","position":2,"name":"Services","item":"https:\/\/www.chu-poitiers.fr\/services\/"},{"@type":"ListItem","position":3,"name":"Pharmacologie clinique et vigilances","item":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/"},{"@type":"ListItem","position":4,"name":"Pharmacog\u00e9n\u00e9tique"}]},{"@type":"WebSite","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/#website","url":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/","name":"Pharmacologie clinique et vigilances","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages\/172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/comments?post=172"}],"version-history":[{"count":2,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages\/172\/revisions"}],"predecessor-version":[{"id":232,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages\/172\/revisions\/232"}],"wp:attachment":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/media?parent=172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}